Interleukin-1 - A major pleiotropic cytokine in tumor-host interactions

Seminars in Cancer Biology

Volumn 12, Issue 4, 2002, Pages 277-290

  Apte, Ron N ^a   Voronov, Elena ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Antitumor immunity; Carcinognesis; IL 1 ; IL 1 ; Immunotherapy; Tumor invasiveness

Indexed keywords

ALPHA CHEMOKINE; BASIC FIBROBLAST GROWTH FACTOR; CD28 ANTIGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN E2; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

B LYMPHOCYTE; CANCER; CANCER IMMUNOTHERAPY; CANCER INVASION; CARCINOGENESIS; CELL INTERACTION; CELL TRANSFORMATION; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG INDUCED DISEASE; ENCAPSULATION; GENE TRANSFER; HEMATOPOIESIS; HOST CELL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MAXIMUM TOLERATED DOSE; MULTIGENE FAMILY; NONHUMAN; PLEIOTROPY; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 0036375050     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-579X(02)00014-7     Document Type: Article

References (104)

1. Biologic basis for interleukin-1 in disease
2. The interleukin-1 receptor complex and interleukin-1 signal transduction
3. The interleukin 1 receptor: Ligand interactions and signal transduction
4. Regulation of inhibitory pathways of the interleukin-1 system
5. Interleukin-1
6. Interleukin 1 and T cell activation
7. CD28/B7 system of T cell costimulation
8. Costimulatory regulation of T cell function
9. IL-1 alpha and TNF-alpha are required for IL-12-induced development of Th1 cells producing high levels of IFN-gamma in BALB/c but not C57BL/6 mice
10. + T cells. Differential effects of IL-1 on helper and inflammatory T cells
11. Role of interleukin 1 in the activation of T lymphocytes
12. T helper cell subsets require the expression of distinct costimulatory signals by antigen-presenting cells
13. CD28-induced costimulation of T helper type 2 cells mediated by induction of responsiveness to interleukin 4
14. Administration of recombinant human IL-1 by Staphylococcus enterotoxin B prevents toleranceinduction in vivo
15. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis
16. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice
17. Modulation of interleukin-1 alpha mRNA expression in mouse epidermis by tumor promoters and antagonists
18. Interleukin-1 alpha gene expression and localization of interleukin-1 alpha protein during tumor promotion
19. Altered expression of interleukin-1 receptor antagonist in different stages of mouse skin carcinogenesis
20. The N-terminal propiece of interleukin 1 alpha is a transforming nuclear oncoprotein
21. Interleukin-1 beta gene deregulation associated with chromosomal rearrangement: A candidate initiating event for murine radiation-myeloid leukemogenesis?
22. Tumor necrosis factor alpha and interleukin 1 alpha induce anchorage independence in v-jun transgenic murine cells
23. Raf-induced transformation requires an interleukin 1 autocrine loop
24. Aberrations in interleukin-1 expression in oncogene-transformed fibrosarcoma lines: Constitutive interleukin-1 alpha transcription and manifestation of biological activity
25. Autocrine interleukin-1 beta production in leukemia: Evidence for the involvement of mutated Ras
26. Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-Ras oncogene
27. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing
28. Tumors are unique organs defined by abnormal signaling and context
29. Proteases in invasion: Matrix metalloproteinases
30. Cytokines as communication signals between leukocytes and endothelial cells
31. The role of CXC chemokines as regulators of angiogenesis
32. Blood vessel formation: What is its molecular basis?
33. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases
34. Interleukin 1 (IL-1)-dependent melanoma hepatic metastasis in vivo increased endothelial adherence by IL-1-induced mannose receptors and growth factor production in vitro
35. IL-18 regulates IL-1 beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1
36. Interleukin 1-induced cancer cell/endothelial cell adhesion in vitro and its relationship to metastasis in vivo: Role of vessel wall 13-HODE synthesis and integrin expression
37. Interleukin 1 receptor antagonist inhibits the augmentation of metastasis induced by interleukin 1 or lipopolysac-charide in a human melanoma/nude mouse system
38. Interleukin-1 receptor antagonist inhibits subcutaneous B16 melanoma growth in vivo
39. Intravital videomicroscopic evidence for regulation of metastasis by the hepatic microvasculature: Effects of interleukin-1 alpha on metastasis and the location of B16F1 melanoma cell arrest
40. Interleukin 1-dependent and -independent mouse melanoma metastases
41. Complementary organ expression of IL-1 vs. IL-6 and CSF-1 activities in normal and LPS-injected mice
42. Distinct patterns of IL-1 alpha and IL-1 beta organ distribution - A possible basis for organ mechanisms of innate immunity
43. Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors
44. Modulation of cell proliferation and cytokine production in AML by recombinant interleukin-1 receptor antagonist
45. Suppression of juvenile chronic myelogenous leukemia colony growth by interleukin-1 receptor antagonist
46. Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: Clinical and prognostic correlates
47. Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation
48. Modulation of acute myeloblastic leukemia (AML) cell proliferation and blast colony formation by antisense oligomer for IL-1 beta converting enzyme (ICE) and IL-1 receptor antagonist (IL-1Ra)
49. Modulatory in vitro effects of interleukin-1 receptor antagonist (IL-1Ra) or antisense oligonucleotide to interleukin-1 beta converting enzyme (ICE) on acute myeloid leukaemia (AML) cell growth
50. Autocrine and paracrine regulation by cytokines and growth factors in melanoma
51. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNF alpha and IL-1 alpha
52. Cancer cell-derived interleukin 1 alpha contributes to autocrine and paracrine induction of pro-metastatic genes in breast cancer
53. Resistance to IL-1 anti-proliferative effect, accompanied by characteristics of advanced melanoma, permits invasion of human melanoma cells in vitro, but not metastasis in the nude mouse
54. Neuroendocrine and immune mediators in prostate cancer progression
55. Interleukin 1 beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells
56. Development of human prostate cancer cells to neuroendocrine-like cells by interleukin-1
57. Expression of interleukin-1 beta in human breast carcinoma
58. Interleukin-1 family expression in human breast cancer: Interleukin-1 receptor antagonist
59. Significant correlation between expression of interleukin-1 alpha and liver metastasis in gastric carcinoma
60. Interleukin-1 receptor antagonist mRNA expression and the progression of gastric carcinoma
61. Autoregulation of the interleukin-1 system and cytokine-cytokine interactions in primary human astrocytoma cells
62. Autocrine interleukin-1 receptor antagonist can support malignant growth of glioblastoma by blocking growth-inhibiting autocrine loop of interleukin-1
63. Interleukin 1 as an adjuvant for active specific immunotherapy in a murine tumor model
64. The induction of specific antitumor immunity by in vivo treatment with interleukin-1 and sonicated tumor extract in a murine model
65. Enhancing effect of interleukin 1 alpha administration on antitumor effector T-cell development
66. Modulation of specific active immunization against murine melanoma using recombinant cytokines
67. Systemic IL-1 and adjuvant treatment of an experimental tumor. I. Immune status following tumor rechallenge
68. Systemic IL-1 and adjuvant treatment of an experimental tumor. II. Immune status during primary tumor challenge
69. Recombinant human interleukin-1 alpha: A potent bioimmunomodifier in vivo in immunosuppressed mice induced by cyclophosphamide, retroviral infection and surgical stress
70. Anti-tumor effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors
71. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: Schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model
72. In vivo stimulation and restoration of the immune response by the noninflammatory fragment 163-171 of human interleukin 1 beta
73. A nine-amino acid peptide from IL-1 beta augments antitumor immune responses induced by protein and DNA vaccines
74. Controlled release of peptides and proteins from biodegradable polyester microspheres; an approach for treating infectious diseases and malignancies
75. Characterization of PLGA microspheres for the controlled delivery of IL-1α for tumor immunotherapy
76. Macrophage activation for the production of immunostimulatory cytokines by delivering interleukin 1 via biodegradable microspheres
77. A novel melanoma gene (MG50) encoding the interleukin 1 receptor antagonist and six epitopes cognized by human cytolytic T lymphocytes
78. Expression of an IL-1 receptor antagonist during mouse hepatocarcinogenesis demonstrated by differential display analysis
79. Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha either spontaneously or following IL-1 alpha gene transfer
80. Interleukin-1 produced by tumorigenic fibroblasts influences tumor rejection
81. Interleukin-1 production by transformed fibroblasts. II. Influence on antigen presentation and T-cell-mediated anti-tumor response
82. Cytokine-induced tumor immunogenicity: Endogenous interleukin-1 alpha expressed by fibrosarcoma cells confers reduced tumorigenicity
83. Differential anti-tumor effects of interleukin-1 (IL-1) alpha and IL-1 beta in cytokine gene-transfer approaches in tumor immunotherapy
84. Opposing effects of IL-1 alpha and IL-1 beta on malignancy patterns. Tumor cell-associated IL-1 alpha potentiates anti-tumor immune responses and tumor regression, whereas IL-1 beta potentiates invasiveness
85. Mechanism responsible for T-cell antigen receptor- and CD28- or interleukin 1 (IL-1) receptor-initiated regulation of IL-2 gene expression by NF-kappaB
86. Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors
87. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha
88. Induction of antitumor immunity with modified autologous cells expressing membrane-bound murine cytokines
89. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model
90. IL-1 alpha gene-transfected human melanoma cells increase tumor-cell adhesion to endothelial cells and their retention in the lung of nude mice
91. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1 alpha expression
92. Protein IL-1/IL-3 gene therapy of non-small cell lung cancer (NSCLC) in rats using 'cracked' adenoproducer cells
93. Fusion of a signal sequence to the interleukin-1 beta gene directs the protein from cytoplasmic accumulation to extracellular release
94. Gene transfer of a hybrid interleukin-1 beta gene to B16 mouse melanoma recruits leucocyte subsetsand reduces tumour growth in vivo
95. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1 beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor
96. Lymphoid hyperplasia in transgenic mice over-expressing a secreted form of the human interleukin-1 beta gene product
97. The toxic and hematologic effects of interleukin-1 alpha administrated in a phase 1 trial to patients with advanced malignancies
98. The effects of treatment with interleukin-1 alpha on platelrt recovery after high-dose carboplatin
99. Phase II trial of interleukin 1 alpha melanoma and indomethacin in treatment of metastatic
100. Induction of interleukin 1 receptor antagonist after interleukin 1 therapy in patients with cancer
101. Interleukin 1 trials in cancer patients: A review of the toxicity, antitumor and hematopoetic effects
102. Active specific immunotherapy for metastatic colorectal carcinoma: Phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 alpha
103. Immunologic approaches to the treatment of prostate cancer